📊 DXCM Key Takeaways
Is Dexcom Inc. (DXCM) a Good Investment?
Dexcom demonstrates exceptional financial health with robust profitability growth (Net Income +45.1% YoY), strong margins across all levels (60.1% gross, 19.6% operating, 17.9% net), and impressive cash generation (1.4B operating cash flow, 23.1% FCF margin). The company maintains fortress-like balance sheet strength with minimal debt (0.00x debt/equity), strong liquidity (1.88x current ratio), and generates substantial free cash flow relative to revenue, positioning it well for sustained growth and shareholder returns.
DexCom shows a high-quality fundamental profile with double-digit revenue growth, much faster earnings growth, and strong free cash flow generation. Profitability is robust across gross, operating, and net margins, while the balance sheet remains very clean with ample liquidity and negligible long-term debt. The combination of growth, operating leverage, and financial strength supports a very favorable fundamental assessment.
Why Buy Dexcom Inc. Stock? DXCM Key Strengths
- Exceptional profitability growth with Net Income +45.1% YoY and EPS +47.2% YoY indicating strong operational leverage
- Premium gross margins at 60.1% demonstrating pricing power and efficient cost of goods sold management
- Best-in-class capital efficiency with ROE of 30.5% and ROA of 13.2% showing excellent asset utilization
- Outstanding cash generation with 1.4B operating cash flow and 23.1% FCF margin providing strategic flexibility
- Pristine balance sheet with negligible debt (2.9M long-term debt), strong cash position (917.7M), and fortress-like financial stability
- Reliable revenue growth of 15.6% YoY demonstrates sustained market demand and recurring revenue model characteristics
- Revenue growth remains strong at 15.6% YoY, indicating continued demand expansion
- Profitability is improving meaningfully, with net income up 45.1% YoY and operating margin at 19.6%
- Financial health is excellent, supported by $917.7M in cash, strong liquidity ratios, minimal debt, and $1.08B in free cash flow
DXCM Stock Risks: Dexcom Inc. Investment Risks
- High insider trading activity (14 Form 4 filings in 90 days) warrants monitoring for potential signaling concerns
- Medical device sector faces regulatory pressures, reimbursement rate changes, and competitive dynamics from larger incumbents
- Margin sustainability dependent on maintaining pricing power and controlling manufacturing costs in competitive market
- Growth quality depends on sustaining current adoption rates as the revenue base gets larger
- Margin expansion could slow if competition, reimbursement pressure, or product mix shifts weigh on gross margin
- Strong current returns may moderate if operating expenses or capital intensity rise faster than revenue
Key Metrics to Watch
- Operating margin trend - critical to confirm operational leverage sustainability
- Free cash flow generation and conversion ratio - essential metric for long-term value creation
- Revenue growth rate - monitor for deceleration signaling market saturation or competitive loss
- Return on equity trajectory - track to ensure capital efficiency remains above 25%
- Gross margin stability - watch for compression from pricing pressure or manufacturing cost inflation
- Gross and operating margin trends
- Revenue growth versus free cash flow conversion
Dexcom Inc. (DXCM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
DXCM Profit Margin, ROE & Profitability Analysis
DXCM vs Healthcare Sector: How Dexcom Inc. Compares
How Dexcom Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dexcom Inc. Stock Overvalued? DXCM Valuation Analysis 2026
Based on fundamental analysis, Dexcom Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dexcom Inc. Balance Sheet: DXCM Debt, Cash & Liquidity
DXCM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dexcom Inc.'s revenue has grown significantly by 90% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.30 reflects profitable operations.
DXCM Revenue Growth, EPS Growth & YoY Performance
DXCM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $994.2M | $134.6M | $0.34 |
| Q2 2025 | $1.0B | $143.5M | $0.35 |
| Q1 2025 | $921.0M | $105.4M | $0.27 |
| Q3 2024 | $975.0M | $120.7M | $0.29 |
| Q2 2024 | $871.3M | $115.9M | $0.28 |
| Q1 2024 | $741.5M | $48.6M | $0.12 |
| Q3 2023 | $769.6M | $101.2M | $0.24 |
| Q2 2023 | $696.2M | $50.9M | $0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Dexcom Inc. Dividends, Buybacks & Capital Allocation
DXCM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dexcom Inc. (CIK: 0001093557)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DXCM
What is the AI rating for DXCM?
Dexcom Inc. (DXCM) has a Combined AI Rating of STRONG BUY from Claude (STRONG BUY) and ChatGPT (STRONG BUY) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DXCM's key strengths?
Claude: Exceptional profitability growth with Net Income +45.1% YoY and EPS +47.2% YoY indicating strong operational leverage. Premium gross margins at 60.1% demonstrating pricing power and efficient cost of goods sold management. ChatGPT: Revenue growth remains strong at 15.6% YoY, indicating continued demand expansion. Profitability is improving meaningfully, with net income up 45.1% YoY and operating margin at 19.6%.
What are the risks of investing in DXCM?
Claude: High insider trading activity (14 Form 4 filings in 90 days) warrants monitoring for potential signaling concerns. Medical device sector faces regulatory pressures, reimbursement rate changes, and competitive dynamics from larger incumbents. ChatGPT: Growth quality depends on sustaining current adoption rates as the revenue base gets larger. Margin expansion could slow if competition, reimbursement pressure, or product mix shifts weigh on gross margin.
What is DXCM's revenue and growth?
Dexcom Inc. reported revenue of $4.7B.
Does DXCM pay dividends?
Dexcom Inc. does not currently pay dividends.
Where can I find DXCM SEC filings?
Official SEC filings for Dexcom Inc. (CIK: 0001093557) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DXCM's EPS?
Dexcom Inc. has a diluted EPS of $2.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DXCM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Dexcom Inc. has a STRONG BUY rating with 90% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is DXCM stock overvalued or undervalued?
Valuation metrics for DXCM: ROE of 30.5% (sector avg: 15%), net margin of 17.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy DXCM stock in 2026?
Our dual AI analysis gives Dexcom Inc. a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is DXCM's free cash flow?
Dexcom Inc.'s operating cash flow is $1.4B, with capital expenditures of $363.5M. FCF margin is 23.1%.
How does DXCM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 17.9% (avg: 12%), ROE 30.5% (avg: 15%), current ratio 1.88 (avg: 2).
Why is DXCM's return on equity (ROE) so high?
Dexcom Inc. has a return on equity of 30.5%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 17.9% net margin.